IL6 and neoplasm: Significantly increased tumour inhibition was observed in mice receiving the combination treatment of antibodies, compared with mice receiving monotherapy of the specific antibodies (CTLA-4 p = 0.0207, interleukin-6 p = 0.0002) [53].